BPC 157 Peptide Dosing
Critical Safety Warning
There are no FDA-approved dosing guidelines for BPC 157, and the compound lacks established safety data in humans for therapeutic use. The FDA label provided 1 appears to be incorrectly attributed, as BPC 157 is not an FDA-approved medication and has no official prescribing information.
Current Evidence Status
Human Safety Data
- A single pilot study in 2 healthy adults demonstrated tolerability of intravenous BPC 157 at 10 mg and 20 mg doses over consecutive days, with no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers 2.
- This represents the only published human safety data for intravenous administration, involving just 2 participants who had prior BPC 157 exposure 2.
- No controlled human trials exist establishing efficacy or optimal dosing for any indication 2.
Animal Research Dosing
The available evidence comes exclusively from rat studies:
- Wound healing and tissue repair studies used doses ranging from 10 picograms to 10 micrograms per kilogram body weight, administered intraperitoneally, orally (in drinking water), or topically 3, 4, 5.
- Tendon-to-bone healing in rats utilized 10 micrograms, 10 nanograms, or 10 picograms per kilogram body weight, given intraperitoneally once daily 6.
- These animal doses demonstrated equipotent effects across a remarkably wide range (microgram to picogram), suggesting a non-linear dose-response relationship 3, 5.
Route of Administration
- Animal studies showed effectiveness via intraperitoneal injection, oral administration, and topical application at injury sites 3, 4, 5.
- The peptide is reportedly stable in human gastric juice, suggesting oral bioavailability 5.
- The single human study used only intravenous infusion over one hour in normal saline 2.
Clinical Reality and Recommendations
Given the absence of FDA approval, lack of human efficacy data, and minimal safety information, BPC 157 cannot be recommended for clinical use outside of properly designed research protocols.
If Considering Use (Research Context Only)
- No established therapeutic dose exists for humans for any indication 2, 3.
- The wide effective range in animals (microgram to picogram doses) provides no clear guidance for human dosing 3, 5.
- Extrapolation from animal studies to humans is unreliable without pharmacokinetic and pharmacodynamic data 2.
Critical Gaps
- No dose-finding studies in humans 2.
- No data on chronic administration safety 2.
- No comparative effectiveness data versus standard treatments 3.
- Unknown drug interactions, contraindications, or long-term effects 2.
- No quality control standards for commercially available preparations 2.
Any use of BPC 157 should occur only within IRB-approved research protocols with appropriate informed consent, safety monitoring, and regulatory oversight 2.